Chinese biotech firm I-Mab launches $111m US listing

Jonathan Breen

January 06, 2020 05:15 am

Nasdaq_alamy_230x150 — CPXNCJ NASDAQ MarketSite building at night in Times Square in Manhattan, New York City. | Alamy Stock Photo

I-Mab, a China-based biopharmaceutical company, has kicked off the roadshow for its up to $111.1m Nasdaq IPO, more than two months after filing draft documents with the US regulator.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

Equity IPOs Health and Biotech Equity China China International Capital Corp Americas Jefferies LLC Asia Greater China Northeast Asia Asia Pacific United States Emerging Markets North America SRI

JB

Jonathan Breen

Equities editor GlobalCapital Asia